168 related articles for article (PubMed ID: 32392959)
21. E1021K Homozygous Mutation in PIK3CD Leads to Activated PI3K-Delta Syndrome 1.
Wang Y; Chen X; Yang Q; Tang W; Jia Y; Zhou L; An Y; Zhang Z; Tang X; Zhao X
J Clin Immunol; 2020 Feb; 40(2):378-387. PubMed ID: 31953711
[TBL] [Abstract][Full Text] [Related]
22. Immunodeficiency due to a novel variant in PIK3CD: a case report.
Shashaani N; Chavoshzadeh Z; Ghasemi L; Ghotbabadi SH; Shiari S; Sharafian S; Shiari R
Pediatr Rheumatol Online J; 2023 Jul; 21(1):71. PubMed ID: 37475052
[TBL] [Abstract][Full Text] [Related]
23. [Two-color flow cytometry analysis of lymphocyte subsets in patients with acute myocardial infarction and post-myocardial infarction syndrome].
Tsuchihashi M; Sakaguchi Y; Nakamura M; Sutani T; Tsuruta S; Kato S; Uemura S; Nishida Y; Hashimoto T; Kagoshima T
J Cardiol; 1995 Aug; 26(2):69-79. PubMed ID: 7674146
[TBL] [Abstract][Full Text] [Related]
24. Secondary C1q Deficiency in Activated PI3Kδ Syndrome Type 2.
Hong Y; Nanthapisal S; Omoyinmi E; Olbrich P; Neth O; Speckmann C; Lucena JM; Gilmour K; Worth A; ; Klein N; Eleftheriou D; Brogan P
Front Immunol; 2019; 10():2589. PubMed ID: 31781101
[TBL] [Abstract][Full Text] [Related]
25. Clinical and Immunological Phenotype of Patients With Primary Immunodeficiency Due to Damaging Mutations in
Klemann C; Camacho-Ordonez N; Yang L; Eskandarian Z; Rojas-Restrepo JL; Frede N; Bulashevska A; Heeg M; Al-Ddafari MS; Premm J; Seidl M; Ammann S; Sherkat R; Radhakrishnan N; Warnatz K; Unger S; Kobbe R; Hüfner A; Leahy TR; Ip W; Burns SO; Fliegauf M; Grimbacher B
Front Immunol; 2019; 10():297. PubMed ID: 30941118
[TBL] [Abstract][Full Text] [Related]
26. Human PIK3R1 mutations disrupt lymphocyte differentiation to cause activated PI3Kδ syndrome 2.
Nguyen T; Lau A; Bier J; Cooke KC; Lenthall H; Ruiz-Diaz S; Avery DT; Brigden H; Zahra D; Sewell WA; Droney L; Okada S; Asano T; Abolhassani H; Chavoshzadeh Z; Abraham RS; Rajapakse N; Klee EW; Church JA; Williams A; Wong M; Burkhart C; Uzel G; Croucher DR; James DE; Ma CS; Brink R; Tangye SG; Deenick EK
J Exp Med; 2023 Jun; 220(6):. PubMed ID: 36943234
[TBL] [Abstract][Full Text] [Related]
27. PI3K Orchestrates T Follicular Helper Cell Differentiation in a Context Dependent Manner: Implications for Autoimmunity.
Preite S; Huang B; Cannons JL; McGavern DB; Schwartzberg PL
Front Immunol; 2018; 9():3079. PubMed ID: 30666254
[TBL] [Abstract][Full Text] [Related]
28. [Clinical and genetic analysis for activated PI3K-δ syndrome by PIK3CD gene mutation].
Liu H; Tang XL; Liu JR; Li HM; Zhao SY
Zhonghua Er Ke Za Zhi; 2016 Sep; 54(9):698-702. PubMed ID: 27596086
[TBL] [Abstract][Full Text] [Related]
29. Blood CD4+CD45RO+CXCR5+ T cells are decreased but partially functional in signal transducer and activator of transcription 3 deficiency.
Mazerolles F; Picard C; Kracker S; Fischer A; Durandy A
J Allergy Clin Immunol; 2013 Apr; 131(4):1146-56, 1156.e1-5. PubMed ID: 23403044
[TBL] [Abstract][Full Text] [Related]
30. ETP-46321, a dual p110α/δ class IA phosphoinositide 3-kinase inhibitor modulates T lymphocyte activation and collagen-induced arthritis.
Aragoneses-Fenoll L; Montes-Casado M; Ojeda G; Acosta YY; Herranz J; Martínez S; Blanco-Aparicio C; Criado G; Pastor J; Dianzani U; Portolés P; Rojo JM
Biochem Pharmacol; 2016 Apr; 106():56-69. PubMed ID: 26883061
[TBL] [Abstract][Full Text] [Related]
31. T-Cell-Specific Loss of the PI-3-Kinase p110α Catalytic Subunit Results in Enhanced Cytokine Production and Antitumor Response.
Aragoneses-Fenoll L; Ojeda G; Montes-Casado M; Acosta-Ampudia Y; Dianzani U; Portolés P; Rojo JM
Front Immunol; 2018; 9():332. PubMed ID: 29535720
[TBL] [Abstract][Full Text] [Related]
32. [A case of autoimmune lymphoproliferactive syndrome and literature review].
Liu L; Hu J; Ma J; Li X; Li F; Li C
Zhonghua Er Ke Za Zhi; 2014 Dec; 52(12):923-6. PubMed ID: 25619350
[TBL] [Abstract][Full Text] [Related]
33. Case Report: Hodgkin Lymphoma and Refractory Systemic Lupus Erythematosus Unveil Activated Phosphoinositide 3-Kinase-δ Syndrome 2 in an Adult Patient.
Conti F; Catelli A; Cifaldi C; Leonardi L; Mulè R; Fusconi M; Stefoni V; Chiriaco M; Rivalta B; Di Cesare S; Schifino G; Sbrega F; Di Matteo G; Ferrari S; Cancrini C; Pession A
Front Pediatr; 2021; 9():702546. PubMed ID: 34307262
[No Abstract] [Full Text] [Related]
34. Activated PI3K-delta syndrome in an Egyptian pediatric cohort with primary immune deficiency.
Ahmed AA; El Shahaway AA; Hussien SA
Allergol Immunopathol (Madr); 2020; 48(6):686-693. PubMed ID: 32349894
[TBL] [Abstract][Full Text] [Related]
35. Abnormalities in the T and NK lymphocyte phenotype in patients with Nijmegen breakage syndrome.
Michałkiewicz J; Barth C; Chrzanowska K; Gregorek H; Syczewska M; Weemaes CM; Madaliński K; Stachowski J;
Clin Exp Immunol; 2003 Dec; 134(3):482-90. PubMed ID: 14632755
[TBL] [Abstract][Full Text] [Related]
36. Activated phosphoinositide 3-dinase delta syndrome (APDS): An update.
Lougaris V; Cancrini C; Rivalta B; Castagnoli R; Giardino G; Volpi S; Leonardi L; La Torre F; Federici S; Corrente S; Cinicola BL; Soresina A; Marseglia GL; Cardinale F
Pediatr Allergy Immunol; 2022 Jan; 33 Suppl 27(Suppl 27):69-72. PubMed ID: 35080319
[TBL] [Abstract][Full Text] [Related]
37. Genetic Defects in Phosphoinositide 3-Kinase δ Influence CD8
Cannons JL; Preite S; Kapnick SM; Uzel G; Schwartzberg PL
Front Immunol; 2018; 9():1758. PubMed ID: 30116245
[TBL] [Abstract][Full Text] [Related]
38. mTOR Promotes Antiviral Humoral Immunity by Differentially Regulating CD4 Helper T Cell and B Cell Responses.
Ye L; Lee J; Xu L; Mohammed AU; Li W; Hale JS; Tan WG; Wu T; Davis CW; Ahmed R; Araki K
J Virol; 2017 Feb; 91(4):. PubMed ID: 27974559
[TBL] [Abstract][Full Text] [Related]
39. CD57 identifies T cells with functional senescence before terminal differentiation and relative telomere shortening in patients with activated PI3 kinase delta syndrome.
Cura Daball P; Ventura Ferreira MS; Ammann S; Klemann C; Lorenz MR; Warthorst U; Leahy TR; Conlon N; Roche J; Soler-Palacín P; Garcia-Prat M; Fuchs I; Fuchs S; Beier F; Brümmendorf TH; Speckmann C; Olbrich P; Neth O; Schwarz K; Ehl S; Rensing-Ehl A
Immunol Cell Biol; 2018 Nov; 96(10):1060-1071. PubMed ID: 29790605
[TBL] [Abstract][Full Text] [Related]
40. Disease Evolution and Response to Rapamycin in Activated Phosphoinositide 3-Kinase δ Syndrome: The European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase δ Syndrome Registry.
Maccari ME; Abolhassani H; Aghamohammadi A; Aiuti A; Aleinikova O; Bangs C; Baris S; Barzaghi F; Baxendale H; Buckland M; Burns SO; Cancrini C; Cant A; Cathébras P; Cavazzana M; Chandra A; Conti F; Coulter T; Devlin LA; Edgar JDM; Faust S; Fischer A; Garcia-Prat M; Hammarström L; Heeg M; Jolles S; Karakoc-Aydiner E; Kindle G; Kiykim A; Kumararatne D; Grimbacher B; Longhurst H; Mahlaoui N; Milota T; Moreira F; Moshous D; Mukhina A; Neth O; Neven B; Nieters A; Olbrich P; Ozen A; Pachlopnik Schmid J; Picard C; Prader S; Rae W; Reichenbach J; Rusch S; Savic S; Scarselli A; Scheible R; Sediva A; Sharapova SO; Shcherbina A; Slatter M; Soler-Palacin P; Stanislas A; Suarez F; Tucci F; Uhlmann A; van Montfrans J; Warnatz K; Williams AP; Wood P; Kracker S; Condliffe AM; Ehl S
Front Immunol; 2018; 9():543. PubMed ID: 29599784
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
